Jamjoom Pharma partners with Bio-Thera to bring biosimilars to MENA

SAUDI ARABIA—Jamjoom Pharmaceuticals Factory Company in Saudi Arabia has partnered with Bio-Thera Solutions Limited, a global leader in biopharmaceutical innovation, to develop advanced therapies and biosimilars.

This collaboration aims to bring new treatment options to the Middle East and North Africa (MENA) region by leveraging the strengths and expertise of both companies.

As part of the agreement, Jamjoom Pharma will hold exclusive rights to commercialize BAT2306, a biosimilar drug currently proposed as an alternative to Novartis’ Cosentyx (secukinumab).

Cosentyx is widely recognized for its effectiveness in treating autoimmune diseases by targeting specific immune system components.

The introduction of BAT2306 in the MENA region represents a crucial step toward increasing the availability of affordable biosimilar therapies for patients.

Under the terms of the partnership, Jamjoom Pharma will be responsible for obtaining regulatory approvals, gaining market access, and managing sales across the MENA region.

This approach ensures the product meets local regulatory standards and reaches patients efficiently.

On the other hand, Bio-Thera will focus on advancing the development of BAT2306 and overseeing its global manufacturing from its state-of-the-art facilities in Guangzhou, China.

This division of duties allows each company to contribute its core competencies towards the successful commercialization of the biosimilar.

Tarek Hosni, CEO of Jamjoom Pharma, emphasized the benefits of this collaboration by highlighting the combination of Bio-Thera’s world-class biosimilar development capabilities with Jamjoom’s thorough understanding of the regional market.

He pointed out that the partnership enables them to deliver high-quality and affordable therapies more effectively.

Hosni also noted that this agreement reinforces Jamjoom Pharma’s leadership in the biopharmaceutical sector and strengthens its role as a trusted partner dedicated to improving healthcare outcomes in the region.

From Bio-Thera’s perspective, Senior Vice President of Business Development Bert Thomas expressed enthusiasm about partnering with Jamjoom Pharma.

He remarked that bringing BAT2306 to patients in MENA aligns with their mission to expand access to advanced treatments globally.

Thomas also conveyed confidence in the collaboration, looking forward to a successful and fruitful partnership.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.